Niercelcarcinoom

Informatie over niercelcarcinoom

Naar schatting is nierkanker wereldwijd de tiende meest voorkomende vorm van kanker¹. Niercelcarcinoom (RCC) is de meest voorkomende vorm van nierkanker en treft jaarlijks bijna 400.000 mensen¹.

Kidney Cancer Factsheet. GLOBOCAN 2018. Accessed: September 2021. Available: gco.iarc.fr/today/data/factsheets/cancers/29-Kidney-fact-sheet.pdf

Expert insights: Prof. Jens Bedke

Prof. Bedke praat in dit interview onder andere over de factoren die de keuze van de eerstelijns- combinatietherapie in RCC mee kunnen bepalen en probeert een typisch patiëntenprofiel te definiëren.

Ontdek meer

Materialen en Presentaties

april 24, 2025

EAU 2025 Highlights – RCC

Niercelcarcinoom, Oncologie, Videos, PDFs & Podcasts

Niercelcarcinoom

Informatie over niercelcarcinoom

Materialen en Presentaties

EAU 2025 Highlights – RCC

ASCO GU 2025 Highlights – RCC

Podcast – NETtalks – Vivre avec une TNE: La voix du patient (Nederlandstalige transcriptie)

ESMO 2024 highlights – RCC

Key Messages -Adjuvant Treatment of RCC by dr. Van Damme (UCL Saint-Luc)

ASCO 2024 highlights – RCC

Cross-border Vision on aRCC Data from ASCO 2024: Q&A Clinical Cases

Cross-border Vision on aRCC Data from ASCO 2024: Q&A 1L+ Systemic Treatment

Cross-border Vision on aRCC Data from ASCO 2024: Clinical Case: Systemic therapy post adjuvant pembrolizumab for RCC

Cross-border Vision on aRCC Data from ASCO 2024: Clinical Case: 1L Systemic Therapy in advanced pRCC by Dr. Koutsoukos, Department of Medical Oncology, Metropolitan Hospital, Athens, Greece

Cross-border Vision on aRCC Data from ASCO 2024: Second Line and Beyond Advanced RCC Management: 2024 Data by Prof. dr. Albiges, Department of Cancer Medicine, Gustave Roussy, France

EAU 2024 highlights – RCC

Key Messages – Local Therapy in RCC Radiotherapy by prof. Berghen (UZ Leuven)

1L aRCC Treatment: IO-TKI by prof. Gennigens (CHU Liège)

Presentation – Local Therapy in RCC Radiotherapy by prof. Berghen (UZ Leuven)

Key Messages – Local Therapy in RCC Cytoreductive Nephrectomy by prof. Albersen (UZ Leuven)

Presentation – Local Therapy in RCC Cytoreductive Nephrectomy by prof. Albersen (UZ Leuven)

Key Messages -Adjuvant Treatment of RCC by dr. Seront (UCL Saint-Luc

ASCO GU Symposium 2024 Highlights: RCC

Key Messages “Adverse Event Management of Systemic Therapy in aRCC Pneumonitis” by prof. Wauters (UZ Leuven)

Key Messages “Adverse Event Management of Systemic Therapy in aRCC Cardiotoxicity” by dr. Von Kemp (UZ Brussel)

Adverse Event Management of Systemic Therapy in aRCC: Pneumonitis by prof. Wauters (UZ Leuven)

Adverse Event Management of Systemic Therapy in aRCC: Cardiotoxicity by dr. Von Kemp (UZ Brussel)

Key messages Immunology in RCC for Dummies by prof. Aspeslagh (UZ Brussel)

1L aRCC Treatment: Brain Metastases by prof. Gennigens (CHU Liège)

2L+ aRCC Treatment by prof. Rottey (UZ Gent)

Key Messages “1L aRCC Treatment: IMDC Favourable Risk Patients & When Do I Stop IO Therapy?” by prof. Beuselinck (UZ Leuven)

1L aRCC Treatment: When Do I Stop IO Therapy? by prof. Beuselinck (UZ Leuven)

1L aRCC Treatment: Favourable IMDC Risk Patients by prof. Beuselinck (UZ Leuven)

Crosstalk predicts clinical benefit of immunotherapy in renal cell carcinoma by dr. Kinget (UZ Leuven)

FORX Project by dr. Verhaert (UZ Brussel)

Crosstalk predicts clinical benefit of immunotherapy in renal cell carcinoma by dr. Kinget (UZ Leuven)

Key Messages “2L+ aRCC Treatment” by prof. Rottey (UZ Gent)

Circulating Biomarkers in aRCC by dr. Carill (CHU Brugmann)

Key Messages “1L aRCC Treatment: IO-TKI & Brain Metastases” by prof. Gennigens (CHU Liège)

Presentation 1L aRCC Treatment: IO-TKI by prof. Gennigens (CHU Liège)

Presentation -Adjuvant Treatment of RCC by dr. Van Damme & dr. Seront (UCL Saint-Luc)

Key Messages – Management of non-clear cell aRCC by dr. Verbiest (UZA)

Presentation – Management of non-clear cell aRCC by dr. Verbiest (UZA)

Videopresentatie over “Adverse Event Management of Systemic Therapy in aRCC: Neurology” door prof. Seynaeve (UZ Brussel) tijdens de Ipsen Masterclass in aRCC in januari 2024 (Engels)

Videopresentatie over “Adverse Event Management of Systemic Therapy in aRCC: Neurology” door prof. Seynaeve (UZ Brussel) tijdens de Ipsen Masterclass in aRCC in januari 2024 (Engels)

Key Messages “1L aRCC Treatment: IO-IO” by dr. Seront (UCL Saint-Luc)

Adverse Event Management of Systemic Therapy in aRCC: Neurology by prof. Seynaeve (UZ Brussel)

Immunology in RCC for Dummies by prof. Aspeslagh (UZ Brussel)

Prostaat fusiebiopsie brochure

Presentatie ESMO 2023 Highlights – Niercelcarcinoom

BIJWERKINGEN – Gewichtsverlies

ZIEKTE EN BEHANDELING – Wat is immuuntherapie?

LEVENSSTIJL – Wat doet het met uw leven?

LEVENSSTIJL – Bewegen

LEVENSSTIJL – Voeding

BIJWERKINGEN – Hand-Voet-Huid reactie

BIJWERKINGEN – Misselijkheid

BIJWERKINGEN – Vermoeidheid

BIJWERKINGEN – Diarree

ZIEKTE EN BEHANDELING – Afspraak bij de oncoloog

ZIEKTE EN BEHANDELING – Wat is een TKI? (Tyrosine Kinase Inhibitor)

ZIEKTE EN BEHANDELING – Gevorderd niercelcarcinoom

ZIEKTE EN BEHANDELING – Wat is niercelcarcinoom?

Expert insights: Prof. Daniel Heng

Expert insights: Prof. Jens Bedke

Expert insights: Prof. Viktor Grünwald

ASCO Symposium 2023 Highlights – Niercelcarcinoom

EAU Symposium 2023 Highlights: RCC

ASCO GU Symposium 2023 Highlights: RCC

BIJWERKINGEN – Hypertensie

Expert insights: Prof. Monty Pal

Expert insights: Prof. David Cella